What’s going on with ZNTL?
Zentalis Pharmaceuticals (ZNTL) stock was trading 6.71% higher after the clinical-stage firm announced it will collaborate with GlaxoSmithKline to evaluate its experimental ovarian cancer treatment. ZNTL shares were up $2.51 per share and traded at $39.92 per share Monday afternoon.
What does this mean for Zentalis Pharmaceuticals?
Investors were clearly enamored enough to snap up ZNTL shares on the news of its clinical collaboration with GlaxoSmithKline, which moves Zentalis Pharmaceuticals’ experimental ovarian cancer treatment along on the path to commercialization. Zentalis has been running clinical studies with ZN-c3 both as a monotherapy and in combination with certain standards of care therapies.
Through the non-exclusive pact, Zentalis will evaluate the combination of ZN-c3, its oral WEE1 inhibitor product candidate, and Zejula (niraparib), Glaxo’s inhibitor, in patients with advanced epithelial ovarian cancer.
“This clinical collaboration and supply agreement with GSK allows us to investigate the broader potential of our WEE1 inhibitor when used as part of a combination treatment with niraparib, a PARP inhibitor,” said Dr. Anthony Sun, chairman and CEO of Zentalis Pharmaceuticals. “As demonstrated in our preclinical studies, ZN-c3 is designed to have significant advantages over other investigational WEE1 inhibitor therapies. We believe this combination has the potential to meaningfully improve the outcomes for patients with ovarian cancer.”
